CeloNova BioSciences's Super-Selective Embolic Microsphere With Drug Loading Capabilities Could Mean Improved Quality Of Life And Overall Survival For Liver Cancer Patients

SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc. (CeloNova), today announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigational device exemption (IDE) clinical trial for its novel ONCOZENE™ embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of Hepatocellular Carcinoma (HCC). HCC is the most common primary liver cancer and accounts for approximately 600,000 deaths annually on a worldwide basis1. Untreated HCC patients have a median survival time of less than 12 months2.

Help employers find you! Check out all the jobs and post your resume.